Difficulty: Medium
Average Score: 94%
Practice
Which drug group requires nursing assessment for the development of abnormal movement disorders in individuals taking therapeutic dosages?
Correct answer
B
Rationale
Antipsychotics (Choice B) are the correct answer because they are strongly associated with the risk of extrapyramidal symptoms (EPS) and other movement disorders due to their dopamine receptor blockade in the nigrostriatal pathway. These disorders include acute dystonia, akathisia, parkinsonism, and tardive dyskinesia, which can develop even at therapeutic doses. First-generation (typical) antipsychotics like haloperidol have a higher risk, but second-generation (atypical) antipsychotics such as risperidone and aripiprazole can also cause these effects. Nurses must monitor for early signs, such as muscle stiffness, restlessness, or involuntary movements, as tardive dyskinesia can become irreversible.
SSRIs (Choice A) primarily affect serotonin reuptake and are not typically linked to movement disorders. While they can cause side effects like agitation or tremors, these are not classified as extrapyramidal symptoms. Rare cases of SSRI-induced akathisia exist, but it is not a hallmark concern like with antipsychotics, making this choice incorrect.
Benzodiazepines (Choice C) act on GABA receptors and are used for anxiety, insomnia, or muscle relaxation. They do not cause EPS or tardive dyskinesia. Instead, they may lead to sedation, dizziness, or dependence, but movement disorders are outside their usual adverse effect profile, ruling them out as the correct answer.
Tricyclic antidepressants (Choice D) primarily inhibit norepinephrine and serotonin reuptake and have anticholinergic effects. While they can cause side effects like dry mouth, constipation, or orthostatic hypotension, they are not associated with EPS or tardive dyskinesia. Their mechanism does not involve dopamine blockade, so movement disorders are not a clinical concern, making this choice incorrect.
The key distinction lies in the pharmacological action: antipsychotics directly interfere with dopamine pathways critical for motor control, while the other drug groups lack this mechanism. Nursing assessments for movement abnormalities are thus essential for antipsychotics but not for SSRIs, benzodiazepines, or tricyclics.
SSRIs (Choice A) primarily affect serotonin reuptake and are not typically linked to movement disorders. While they can cause side effects like agitation or tremors, these are not classified as extrapyramidal symptoms. Rare cases of SSRI-induced akathisia exist, but it is not a hallmark concern like with antipsychotics, making this choice incorrect.
Benzodiazepines (Choice C) act on GABA receptors and are used for anxiety, insomnia, or muscle relaxation. They do not cause EPS or tardive dyskinesia. Instead, they may lead to sedation, dizziness, or dependence, but movement disorders are outside their usual adverse effect profile, ruling them out as the correct answer.
Tricyclic antidepressants (Choice D) primarily inhibit norepinephrine and serotonin reuptake and have anticholinergic effects. While they can cause side effects like dry mouth, constipation, or orthostatic hypotension, they are not associated with EPS or tardive dyskinesia. Their mechanism does not involve dopamine blockade, so movement disorders are not a clinical concern, making this choice incorrect.
The key distinction lies in the pharmacological action: antipsychotics directly interfere with dopamine pathways critical for motor control, while the other drug groups lack this mechanism. Nursing assessments for movement abnormalities are thus essential for antipsychotics but not for SSRIs, benzodiazepines, or tricyclics.